ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) breakthrough cancer diagnostic is better than the existing technology in harvesting head and neck cancer cells, according to work carried out in Greece.
The results of the study by the University of Athens and Attikon University Hospital will be presented at the American Association for Cancer Research conference later. ANGLE calls them “highly encouraging”.
Delegates will hear the Parsortix system was more sensitive and harvested cancer cells circulating in the bloodstream at greater purity than the existing antibody-based approach.
A total of 40 patients were trialled using the two approaches. It was also found information on the expression of key genes could be garnered from the Parsortix samples.
This crucial data helps assess the likely response of cancer patients to treatments such as immunotherapies and has the potential to be of “significant clinical importance for the therapy selection and follow-up of patients”, ANGLE said.
"The advantages of the Parsortix system, in head and neck cancer, over the existing antibody-based approaches increases the market opportunity available to ANGLE,” explained the company’s founder Andrew Newland.
“The University of Athens is a leader in CTC [circulating tumour cell] research and the successful completion of this work by a customer validates a key element of our roll-out strategy of using.”